U.S. Markets closed

Myriad Genetics guidance still looks conservative, says Cowen

Cowen believes Myriad Genetics increased guidance remains conservative citing improved margins and tax rates, and assumptions that include no increase to the Companion Diagnostics revenue range and expectations that BART percentage usage remains the same. Shares are Outperform rated.